Published in Arthritis Res Ther on June 22, 2005
Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther (2009) 1.27
T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood (2007) 1.11
Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis. Clin Exp Immunol (2010) 0.92
Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice. PLoS One (2013) 0.92
CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol (2015) 0.89
Enhanced activation of memory, but not naïve, B cells in chronic hepatitis C virus-infected patients with cryoglobulinemia and advanced liver fibrosis. PLoS One (2013) 0.86
A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis. PLoS One (2010) 0.86
Expression of chemokine receptors CXCR4, CXCR5 and CCR7 on B and T lymphocytes from patients with primary antibody deficiency. Clin Exp Immunol (2009) 0.85
Lymphocyte migration into atherosclerotic plaque. Arterioscler Thromb Vasc Biol (2014) 0.85
Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. Front Immunol (2014) 0.84
B cells as effectors and regulators of sex-biased arthritis. Autoimmunity (2012) 0.82
Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis. Arthritis Res Ther (2009) 0.82
Infection of Female BWF1 Lupus Mice with Malaria Parasite Attenuates B Cell Autoreactivity by Modulating the CXCL12/CXCR4 Axis and Its Downstream Signals PI3K/AKT, NFκB and ERK. PLoS One (2015) 0.81
Expression of CXCL12 receptors in B cells from Mexican Mestizos patients with systemic Lupus erythematosus. J Transl Med (2012) 0.78
Increased CXCR3 Expression of Infiltrating Plasma Cells in Hunner Type Interstitial Cystitis. Sci Rep (2016) 0.77
Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users. PLoS One (2016) 0.77
Analysis of subsets of B cells, Breg, CD4Treg and CD8Treg cells in adult patients with primary selective IgM deficiency. Am J Clin Exp Immunol (2016) 0.76
Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis. Arthritis Res Ther (2009) 0.76
Polychromatic flow cytometry in evaluating rheumatic disease patients. Arthritis Res Ther (2015) 0.76
Gq-Coupled Receptors in Autoimmunity. J Immunol Res (2016) 0.75
[Translational aspects on the role of B-cells in autoimmune diseases. "From bench to bedside" and "from bed to benchside"]. Z Rheumatol (2009) 0.75
Expression of CCR6 on B cells in systemic lupus erythematosus patients. Clin Rheumatol (2017) 0.75
Selective IgM Deficiency-An Underestimated Primary Immunodeficiency. Front Immunol (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Chemokines: a new classification system and their role in immunity. Immunity (2000) 13.03
A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell (1996) 5.97
Lymphocyte traffic control by chemokines. Nat Immunol (2001) 4.86
Lymphoid neogenesis in rheumatoid synovitis. J Immunol (2001) 3.63
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol (2000) 3.05
Expression of the G-protein--coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. Blood (1994) 2.93
Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol (2002) 2.37
Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J Leukoc Biol (1999) 2.34
Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol (2000) 2.17
Chemokines in immunity. Adv Immunol (2001) 2.03
Developmental switches in chemokine response profiles during B cell differentiation and maturation. J Exp Med (2000) 1.96
Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum (2001) 1.91
Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol (2001) 1.85
CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol (2001) 1.85
Chemokines in inflammation and immunity. Immunol Today (2000) 1.82
Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol (1999) 1.71
Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum (2004) 1.66
Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood (2005) 1.51
CD4+CD3- cells induce Peyer's patch development: role of alpha4beta1 integrin activation by CXCR5. Immunity (2002) 1.49
Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum (2001) 1.49
Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol (2003) 1.49
The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood (2000) 1.35
In vivo differentiated cytokine-producing CD4(+) T cells express functional CCR7. J Immunol (2002) 1.32
Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis. Clin Exp Immunol (2001) 1.30
Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine (2000) 1.29
Chemokines and B-cell homing to follicles. Curr Top Microbiol Immunol (1999) 1.17
The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest (1999) 1.09
Michael Mason prize essay 2003. Why do leucocytes accumulate within chronically inflamed joints? Rheumatology (Oxford) (2003) 1.03
The immunopathogenesis of rheumatoid arthritis. Curr Opin Rheumatol (1991) 0.98
Homing chemokines in rheumatoid arthritis. Arthritis Res (2002) 0.97
Chemokine receptor expression on B cells and effect of interferon-beta in multiple sclerosis. J Neuroimmunol (2002) 0.94
Aberrant activation of B cells in patients with rheumatoid arthritis. Ann N Y Acad Sci (2003) 0.84
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol (2006) 5.22
Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood (2004) 3.17
Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol (2011) 2.83
High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat Biotechnol (2013) 2.81
New glucocorticoids on the horizon: repress, don't activate! J Rheumatol (2005) 2.70
Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (2003) 2.32
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register. Arthritis Res Ther (2006) 2.15
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol (2012) 2.12
Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood (2004) 2.05
Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum (2008) 2.00
Memory B and memory plasma cells. Immunol Rev (2010) 1.95
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.93
Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood (2008) 1.91
The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol (2014) 1.87
Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem (2007) 1.86
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol (2011) 1.82
Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum (2009) 1.81
Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol (2002) 1.80
Plasma cell differentiation and survival. Curr Opin Immunol (2008) 1.71
Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum (2004) 1.66
Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjögren's syndrome. Arthritis Rheum (2005) 1.65
Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum (2008) 1.64
Immunopathogenic mechanisms of systemic autoimmune disease. Lancet (2013) 1.63
In silico subtraction approach reveals a close lineage relationship between follicular dendritic cells and BP3(hi) stromal cells isolated from SCID mice. Eur J Immunol (2010) 1.60
Origin and functional activity of the membrane-bound glucocorticoid receptor. Arthritis Rheum (2011) 1.59
Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood (2010) 1.57
Acute intravascular hemolysis after transfusion of a chimeric RBC unit. Transfusion (2003) 1.55
Cis- and trans-acting gene regulation is associated with osteoarthritis. Am J Hum Genet (2006) 1.55
Immunoglobulin kappa light chain gene rearrangement is impaired in mice deficient for DNA polymerase mu. Immunity (2003) 1.53
Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum (2008) 1.53
Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc Natl Acad Sci U S A (2014) 1.50
Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum (2002) 1.47
Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol (2005) 1.46
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum (2004) 1.45
BMP2 initiates chondrogenic lineage development of adult human mesenchymal stem cells in high-density culture. Differentiation (2003) 1.42
A serologic marker for fetal risk of congenital heart block. Arthritis Rheum (2002) 1.38
Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A (2009) 1.38
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis (2011) 1.37
Adaptation of humoral memory. Immunol Rev (2006) 1.29
Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence tests. Arthritis Res Ther (2010) 1.29
In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol (2007) 1.25
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells. J Immunol (2010) 1.20
New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. Curr Opin Rheumatol (2003) 1.19
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. Rheumatology (Oxford) (2011) 1.18
Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis (2012) 1.18
B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol (2007) 1.18
Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun Rev (2009) 1.17
B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther (2007) 1.16
Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis (2011) 1.15
Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther (2010) 1.12
High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol (2006) 1.10
Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun Rev (2006) 1.09
The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev (2013) 1.09
CD38 low IgG-secreting cells are precursors of various CD38 high-expressing plasma cell populations. J Leukoc Biol (2004) 1.08
Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. Arthritis Rheum (2004) 1.08
Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. Clin Immunol (2008) 1.07
Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet (2005) 1.06
Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.05
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis (2013) 1.05
Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study. Arthritis Res Ther (2006) 1.05
Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndrome. Arthritis Rheum (2006) 1.05
Stem cells for regenerative medicine: advances in the engineering of tissues and organs. Naturwissenschaften (2002) 1.04
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis (2012) 1.04
Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. Ann Rheum Dis (2009) 1.04
Human CD4(+) T cells maintain specific functions even under conditions of extremely restricted ATP production. Eur J Immunol (2008) 1.03
Osteoarthritis synovial fluid activates pro-inflammatory cytokines in primary human chondrocytes. Int Orthop (2012) 1.02
In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum (2011) 1.02
IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis (2012) 0.99
B cells identified according to their expression of CD19 and surface Ig are depleted from peripheral blood by rituximab in patients with rheumatoid arthritis: comment on the article by Jones et al. Arthritis Rheum (2013) 0.99
V-region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis. Arthritis Rheum (2011) 0.98
Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis. Virchows Arch (2002) 0.98
Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther (2005) 0.97
Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. J Med Genet (2013) 0.96
Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag (2007) 0.95
The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigens. Dtsch Arztebl Int (2009) 0.95
Immunization induces activation of bone marrow eosinophils required for plasma cell survival. Eur J Immunol (2011) 0.95
Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment. Arthritis Rheum (2009) 0.95
Adaptation of human CD4+ T cells to pathophysiological hypoxia: a transcriptome analysis. J Rheumatol (2009) 0.95
Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum (2011) 0.95
Class switching and consecutive loss of dsDNA-reactive B1a B cells from the peritoneal cavity during murine lupus development. Eur J Immunol (2010) 0.94
MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain (2013) 0.94
Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther (2014) 0.94
Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia. Blood (2012) 0.93
More night than day--circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J Rheumatol (2010) 0.93
Diversification of Ig heavy chain genes in human preterm neonates prematurely exposed to environmental antigens. J Immunol (2002) 0.93
Fatigue and depression predict physician visits and work disability in women with primary Sjögren's syndrome: results from a cohort study. Rheumatology (Oxford) (2011) 0.92
Prevalence of malnutrition in hospitalized medical patients: impact of underlying disease. Dig Dis (2003) 0.92
Long-lived plasma cells in immunity and immunopathology. Immunol Lett (2005) 0.92